ATE201594T1 - Verwendung von venlafaxin oder eines aryloxy- propanaminderivates zur herstellung eines medikaments zur behandlung von inkontinenz - Google Patents

Verwendung von venlafaxin oder eines aryloxy- propanaminderivates zur herstellung eines medikaments zur behandlung von inkontinenz

Info

Publication number: ATE201594T1
Authority: AT; Austria
Prior art keywords: venlafaxine; incontinence; aryloxypropanemin; medication; derivative
Prior art date: 1993-11-24

Application number

AT94308604T

Other languages

English (en)

Inventor

Karl Bruce Thor

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-24

Filing date

1994-11-22

Publication date

2001-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22566762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE201594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-11-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-06-15 Application granted granted Critical

2001-06-15 Publication of ATE201594T1 publication Critical patent/ATE201594T1/de

Links

PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title abstract 2
229960004688 venlafaxine Drugs 0.000 title abstract 2
206010021639 Incontinence Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
-1 aryloxy propanamines Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Furan Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyridine Compounds (AREA)
External Artificial Organs (AREA)

AT94308604T 1993-11-24 1994-11-22 Verwendung von venlafaxin oder eines aryloxy- propanaminderivates zur herstellung eines medikaments zur behandlung von inkontinenz ATE201594T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15812193A	1993-11-24	1993-11-24

Publications (1)

Publication Number	Publication Date
ATE201594T1 true ATE201594T1 (de)	2001-06-15

Family

ID=22566762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94308604T ATE201594T1 (de)	1993-11-24	1994-11-22	Verwendung von venlafaxin oder eines aryloxy- propanaminderivates zur herstellung eines medikaments zur behandlung von inkontinenz

Country Status (27)

Country	Link
US (1)	US5744474A (de)
EP (1)	EP0654264B1 (de)
JP (1)	JP3681009B2 (de)
KR (1)	KR100347277B1 (de)
CN (1)	CN1099284C (de)
AT (1)	ATE201594T1 (de)
AU (1)	AU679269B2 (de)
CA (1)	CA2136120C (de)
CY (2)	CY2245B1 (de)
CZ (1)	CZ289069B6 (de)
DE (2)	DE69427337T2 (de)
DK (1)	DK0654264T3 (de)
ES (1)	ES2157958T3 (de)
GE (1)	GEP20064000B (de)
GR (1)	GR3036446T3 (de)
HU (1)	HU218920B (de)
IL (1)	IL111705A (de)
LU (1)	LU91140I2 (de)
NL (1)	NL300174I2 (de)
NO (2)	NO313535B1 (de)
PH (1)	PH30741A (de)
PT (1)	PT654264E (de)
RU (1)	RU2152786C2 (de)
SI (1)	SI0654264T1 (de)
TW (1)	TW344661B (de)
UA (1)	UA32429C2 (de)
ZA (1)	ZA949190B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506270A (en) *	1995-01-30	1996-04-09	American Home Products Corporation	Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
JP2000506863A (ja) *	1996-03-11	2000-06-06	イーライ・リリー・アンド・カンパニー	間質性膀胱炎の治療または予防方法
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
EP1331003B1 (de) *	1996-03-25	2015-08-26	Wyeth LLC	Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
US6274171B1 (en)	1996-03-25	2001-08-14	American Home Products Corporation	Extended release formulation of venlafaxine hydrochloride
US6150396A (en) *	1997-03-07	2000-11-21	Eli Lilly And Company	Methods of treating or preventing interstitial cystitis
US6579899B1 (en)	1998-07-16	2003-06-17	Massachusetts Institute Of Technology	Composition for treatment of stress
EP1096927A4 (de) *	1998-07-16	2002-09-04	Massachusetts Inst Technology	Zusammensetzung für stressbehandlung
CZ302630B6 (cs) *	1998-08-27	2011-08-10	Pharmacia & Upjohn Ab	Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
US6046242A (en) *	1998-11-27	2000-04-04	Basf Aktiengesellschaft	Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) *	1998-12-01	2002-01-29	Sepracor, Inc.	Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en)	1998-12-01	2001-03-06	Sepracor, Inc.	Derivatives of (+)-venlafaxine and methods of preparing and using the same
HUP0200898A3 (en)	1999-04-06	2005-09-28	Sepracor Inc	Derivatives of venlafaxine and methods of preparing and using the same
ES2246488T3 (es) *	1999-07-01	2006-02-16	PHARMACIA & UPJOHN COMPANY LLC	Reboxetina para tratar la migraña.
US7291646B2 (en)	1999-11-24	2007-11-06	Wyeth	Ethers of O-desmethyl venlafaxine
US6572890B2 (en) *	2000-01-13	2003-06-03	Osmotica Corp.	Osmotic device containing venlafaxine and an anti-psychotic agent
DE10027290C2 (de)	2000-06-02	2002-07-11	Basf Coatings Ag	Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung
DE10059412A1 (de)	2000-11-30	2002-06-13	Gruenenthal Gmbh	Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
EP2319826A1 (de) *	2001-02-12	2011-05-11	Wyeth LLC	O-Desmethyl-Venlafaxine Succinat Salz
US6602911B2 (en)	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
UA77234C2 (en) *	2001-12-05	2006-11-15	Wyeth Corp	Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
AU2002348266A1 (en) *	2001-12-05	2003-06-23	Wyeth	Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
GB0202265D0 (en) *	2002-01-31	2002-03-20	Arachnova Therapeutics Ltd	New therapeutic use
WO2003082805A1 (en) *	2002-03-28	2003-10-09	Synthon B.V.	Low water-soluble venlafaxine salts
CN1662231A (zh) *	2002-04-24	2005-08-31	柏树生物科学公司	包括应激相关障碍在内的功能性躯体障碍的预防与治疗
DE10224107A1 (de) *	2002-05-29	2003-12-11	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
US20040197397A1 (en) *	2002-08-30	2004-10-07	Watson Pharmaceuticals, Inc.	Drug delivery system for treatment of urinary incontinence
GB0221438D0 (en) *	2002-09-16	2002-10-23	Avecia Ltd	Processes and compounds
EP1424079A1 (de) *	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
US20070077301A1 (en) *	2002-12-23	2007-04-05	Meyer Glenn A	Venlafaxine osmotic device formulation
ATE365554T1 (de) *	2003-04-04	2007-07-15	Dynogen Pharmaceuticals Inc	Methode zur behandlung von erkrankungen der unteren harnwege
AU2005238296A1 (en) *	2004-04-30	2005-11-10	Warner-Lambert Company Llc	Substituted morpholine compounds for the treatment of central nervous system disorders
EP1792629A4 (de)	2004-08-25	2010-08-25	Takeda Pharmaceutical	Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
TWI306858B (en) *	2004-12-23	2009-03-01	Teva Pharma	Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1858874A1 (de) *	2005-03-14	2007-11-28	Teva Pharmaceutical Industries Ltd.	(s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamin-di-p-toluoyl-l-tartarat und herstellungsverfahren
US7842717B2 (en)	2005-09-22	2010-11-30	Teva Pharmaceutical Industries Ltd.	DNT-maleate and methods of preparation thereof
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
PT1954669E (pt)	2005-12-01	2015-10-23	Auspex Pharmaceuticals Inc	Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
JP2009518407A (ja)	2005-12-05	2009-05-07	ワイス	置換１−（２−アミノ−１−フェニル−エチル）−シクロヘキサノールのエナンチオマーを選択的に合成するための方法
US7759500B2 (en)	2005-12-05	2010-07-20	Teva Pharmaceutical Industries Ltd.	2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
EP1826204A1 (de)	2006-02-28	2007-08-29	Laboratorios Del Dr. Esteve, S.A.	Verfahren zur Herstellung enantomerer Ausgangsverbindungen von Duloxetin
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
ES2693948T3 (es)	2007-03-15	2018-12-14	Auspex Pharmaceuticals, Inc.	Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
WO2020014336A1 (en)	2018-07-11	2020-01-16	Dignify Therapeutics, Llc	Method of treating voiding dysfunction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4018895A (en) *	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
ZA817863B (en) *	1980-11-14	1983-06-29	Lilly Co Eli	(-)n-methyl-3-(2-methylphenoxy)-3-phenylpropylamnie,antidepressant
IE56324B1 (en) *	1982-12-13	1991-06-19	American Home Prod	Phenethylamine derivatives and intermediates therefor
US4761501A (en) *	1983-10-26	1988-08-02	American Home Products Corporation	Substituted phenylacetamides
KR880007433A (ko) *	1986-12-22	1988-08-27	메리 앤 터커	3-아릴옥시-3-치환된 프로판아민
US4956388A (en) *	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
CA1329937C (en) *	1987-04-09	1994-05-31	Dennis Charles Thompson	1-phenyl-3-naphthalenyloxypropanamines
SE8804003D0 (sv) *	1988-11-04	1988-11-04	Pharmacia Ab	Compounds for the treatment of urinary incontinence
US5236956A (en) *	1988-11-04	1993-08-17	Kabi Pharmacia Aktiebolag	Compounds for the treatment of urinary incontinence
US5250571A (en) *	1988-11-14	1993-10-05	Eli Lilly And Company	(S)-norfluoxetine in method of inhibiting serotonin uptake
DE3912232A1 (de) *	1989-04-11	1989-11-30	Klosa Josef	Mittel gegen harninkontinenz
PH30083A (en) *	1991-02-25	1996-12-27	Lilly Co Eli	Treatment of lower urinary tract disorders
DK0537915T3 (da) *	1991-09-27	1995-11-27	Lilly Co Eli	N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
US5281624A (en) *	1991-09-27	1994-01-25	Eli Lilly And Company	N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ATE170747T1 (de) *	1991-12-21	1998-09-15	Smithkline Beecham Plc	Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1994
- 1994-05-12 TW TW083104298A patent/TW344661B/zh not_active IP Right Cessation
- 1994-11-18 ZA ZA949190A patent/ZA949190B/xx unknown
- 1994-11-18 CA CA002136120A patent/CA2136120C/en not_active Expired - Lifetime
- 1994-11-21 UA UA94119056A patent/UA32429C2/uk unknown
- 1994-11-21 PH PH49414A patent/PH30741A/en unknown
- 1994-11-21 NO NO19944456A patent/NO313535B1/no not_active IP Right Cessation
- 1994-11-21 IL IL11170594A patent/IL111705A/en not_active IP Right Cessation
- 1994-11-22 PT PT94308604T patent/PT654264E/pt unknown
- 1994-11-22 JP JP28811994A patent/JP3681009B2/ja not_active Expired - Lifetime
- 1994-11-22 ES ES94308604T patent/ES2157958T3/es not_active Expired - Lifetime
- 1994-11-22 SI SI9430379T patent/SI0654264T1/xx unknown
- 1994-11-22 DE DE69427337T patent/DE69427337T2/de not_active Expired - Lifetime
- 1994-11-22 AU AU78968/94A patent/AU679269B2/en not_active Expired
- 1994-11-22 DK DK94308604T patent/DK0654264T3/da active
- 1994-11-22 EP EP94308604A patent/EP0654264B1/de not_active Expired - Lifetime
- 1994-11-22 DE DE1994627337 patent/DE122005000005I2/de active Active
- 1994-11-22 AT AT94308604T patent/ATE201594T1/de active
- 1994-11-22 KR KR1019940030696A patent/KR100347277B1/ko not_active Expired - Lifetime
- 1994-11-23 CN CN94118993A patent/CN1099284C/zh not_active Expired - Lifetime
- 1994-11-23 CZ CZ19942893A patent/CZ289069B6/cs not_active IP Right Cessation
- 1994-11-23 RU RU94041950/14A patent/RU2152786C2/ru active
- 1994-11-23 HU HU9403369A patent/HU218920B/hu unknown
1995
- 1995-04-20 US US08/425,703 patent/US5744474A/en not_active Expired - Lifetime
2001
- 2001-08-27 GR GR20010401296T patent/GR3036446T3/el unknown
- 2001-11-14 CY CY0100037A patent/CY2245B1/xx unknown
2005
- 2005-02-04 LU LU91140C patent/LU91140I2/fr unknown
- 2005-02-09 NO NO2005004C patent/NO2005004I1/no unknown
- 2005-02-10 CY CY2005002C patent/CY2005002I1/el unknown
- 2005-02-10 NL NL300174C patent/NL300174I2/nl unknown
2006
- 2006-05-23 GE GEAP20069411A patent/GEP20064000B/en unknown

Also Published As

Publication number	Publication date
HK1013799A1 (en)	1999-09-10
DE122005000005I2 (de)	2006-06-08
NL300174I1 (nl)	2005-04-01
JP3681009B2 (ja)	2005-08-10
NO2005004I1 (no)	2005-02-10
DE122005000005I1 (de)	2005-05-12
JPH07188003A (ja)	1995-07-25
HU9403369D0 (en)	1995-02-28
NL300174I2 (nl)	2005-05-02
ZA949190B (en)	1996-05-20
RU2152786C2 (ru)	2000-07-20
CY2005002I2 (el)	2010-07-28
DE69427337D1 (de)	2001-07-05
CN1107699A (zh)	1995-09-06
GR3036446T3 (en)	2001-11-30
KR100347277B1 (ko)	2003-03-06
LU91140I2 (fr)	2005-04-04
UA32429C2 (uk)	2000-12-15
HUT72317A (en)	1996-04-29
CY2005002I1 (el)	2010-07-28
DE69427337T2 (de)	2001-10-31
NO944456L (no)	1995-05-26
RU94041950A (ru)	1996-09-20
US5744474A (en)	1998-04-28
DK0654264T3 (da)	2001-07-30
CA2136120A1 (en)	1995-05-25
CY2245B1 (en)	2003-07-04
KR950013511A (ko)	1995-06-15
CZ289394A3 (en)	1995-07-12
NO944456D0 (no)	1994-11-21
HU218920B (hu)	2000-12-28
CA2136120C (en)	2008-01-29
GEP20064000B (en)	2006-12-11
TW344661B (en)	1998-11-11
CZ289069B6 (cs)	2001-10-17
AU679269B2 (en)	1997-06-26
IL111705A (en)	2001-01-11
EP0654264B1 (de)	2001-05-30
NO313535B1 (no)	2002-10-21
PH30741A (en)	1997-10-17
IL111705A0 (en)	1995-01-24
PT654264E (pt)	2001-09-28
CN1099284C (zh)	2003-01-22
SI0654264T1 (en)	2001-10-31
AU7896894A (en)	1995-06-01
EP0654264A1 (de)	1995-05-24
ES2157958T3 (es)	2001-09-01

Publication	Publication Date	Title
DE122005000005I1 (de)	2005-05-12	Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE122005000002I1 (de)	2005-05-12	Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
ATE249228T1 (de)	2003-09-15	Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
DE69524679D1 (de)	2002-01-31	Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
ATE141505T1 (de)	1996-09-15	Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69435330D1 (de)	2011-01-27	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
ATE133336T1 (de)	1996-02-15	Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
DE69629184D1 (de)	2003-08-28	Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus
DE69310065D1 (de)	1997-05-28	Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
DE69229944D1 (de)	1999-10-14	Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
DE69232911D1 (de)	2003-03-06	Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
DE69426320D1 (de)	2000-12-28	Verwendung von silikon/fluorsilikon kopolymeröl zur herstellung eines arzneimittels zur behandlung von augenerkrankungen
ATE109350T1 (de)	1994-08-15	Verwendung von ofloxacin oder dessen salzen zur herstellung eines lokalpräparats für die behandlung von otopathie.
DE69423577D1 (de)	2000-04-27	Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
ATE148628T1 (de)	1997-02-15	5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
DE69301750D1 (de)	1996-04-18	Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE69716341D1 (de)	2002-11-21	Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen
DE69026511D1 (de)	1996-05-15	Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE68903907D1 (de)	1993-01-28	Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
ATE169226T1 (de)	1998-08-15	Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre
DE69632677D1 (de)	2004-07-15	Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
DE68916777D1 (de)	1994-08-18	Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
ATE173921T1 (de)	1998-12-15	Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
DE69610045D1 (de)	2000-10-05	Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
DE69022014D1 (de)	1995-10-05	Verfahren zur Herstellung von S-(+)-3-Halogeno-1,2-propandiol durch Behandlung mit Mikroorganismen.